CloudMD: Canaccord Reiterates $3.25 Price Target Following Acquisition

This morning, CloudMD Software & Services (TSXV: DOC) announced that they purchased Rx Infinity, an e-commerce specialty pharmacy, and wholesaler, for $2.5 million in cash, $4 million in shares, and a performance-based earnout of $3 million for a total consideration of $9.5 million.

RX Infinity is a Mississauga, ON-based specialty pharmacy and wholesaler serving patients mainly in Ontario, but can distribute nationwide to a network of over 500 independent pharmacies.

CloudMD currently has four analysts covering the company with a weighted 12-month price target of C$3.58. This is slightly up from the average last month, which was C$3.45. One analyst has a strong buy rating, while the other three have buy ratings on the company.

Canaccord Genuity reiterated their Speculative Buy rating alongside their C$3.25 12-month price target on CloudMD this morning following the announcement. Doug Taylor, Canaccord’s analyst, headlines, “Brisk pace of M&A continues with online specialty pharma acquisition.” Taylor believes that this deal will bring top-line synergies to support CloudMD’s growing primary care network, existing pharmacy footprint and will grow its relationship with pharmaceutical manufacturers.

Taylor writes, “With Rxi and assuming the close of its remaining outstanding deals, CloudMD now has a $60M revenue run rate and ~$42M in net cash for additional accretive M&A to extend its physical and digital health footprint”.

Taylor says RX Infinity, “adds a complimentary online footprint and expands the company’s presence into Ontario and other provincial markets,” while the company says it expects synergies from connecting its primary care network and EMR platform with RX Infinity.

Below you can see the new 2020/2021 estimates, which have been raised on the back of this acquisition. Taylor adds, “we have adjusted our Q4/20 expectations to reflect the updated timing of contributions from the company’s HumanaCare, Medical Confidence, and Canadian Medical Directory acquisitions, which all closed in January”.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Silver47 Completes Property-Wide Geochemical, Rock Sampling Program At Adams Plateau, Identifies Numerous Targets

Altamira Gold Identifies Presence Of Second Mineralized Porphyry Body At Cajueiro

Related News

Verano Holdings: Canaccord Reiterates $35 Price Target

On April 8th, Verano Holdings (CSE: VRNO) announced their full year 2020 and fourth quarter...

Sunday, April 11, 2021, 01:45:00 PM

Organigram: Haywood Raises Estimates Betting On Increased Market Share

On January 11th, Organigram Holdings (TSX: OGI) issued its second fiscal quarter earnings for 2022....

Saturday, January 15, 2022, 11:09:00 AM

WeCommerce: Canaccord Reiterates $20 Price Target After Lumpy Quarter

On August 26, WeCommerce (TSXV: WE) reported its second quarter financial results. The company announced...

Wednesday, September 1, 2021, 11:40:00 AM

Lundin Gold Sees BMO Capital Markets Raise 2022 Production Estimates

Last week, Lundin Gold Inc. (TSX: LUG) announced its second-quarter production results. The company said...

Monday, July 11, 2022, 02:18:00 PM

Aurora Cannabis: Stifel Lowers Rating To Hold, Price Target Falls To $10.50 From $16

Yesterday, Aurora Cannabis (TSX: ACB) (NYSE: ACB) provided a business update. The firm announced that...

Wednesday, September 9, 2020, 01:47:00 PM